Pfizer Corporation

Alan Elwood Blize

Peter Bertinato

Hengmiao Cheng

Brian S Bronk

Hiep Huatan

Jin Li

Clive Mason

John P Dirlam

Hamish Alastair Irvine McArthur

Robert J Rafka

Colman B Ragan

Carl Bernard Ziegler

Barry J Morton

The invention relates to triamide MTP/ApoB inhibitors of the formula 1 wherein R-Rare as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.

Triamide-substituted heterobicyclic compounds

The invention relates to novel erythromycin analogs and azalides, particularly ones with novel C-13 substituents, and to pharmaceutically acceptable salts thereof. The compounds of this invention are antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention also relates to pharmaceutical compositions containing such compounds and to methods of treating bacterial protozoa infections by administering such compounds. The invention also relates to methods of preparing such compounds and to intermediates useful in such preparation.

Macrolides

The invention relates to triamide MTP/ApoB inhibitors of the formula 1wherein R-Rare as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.

The invention relates to a method of preparing compounds of the formula 1

13-membered azalides and their use as antibiotic agents

Growing community of inventors

New London, CT, United States of America

Alan Elwood Blize